Logo image of ATYR

ATYR PHARMA INC (ATYR) Stock Fundamental Analysis

NASDAQ:ATYR - Nasdaq - US0021202025 - Common Stock - Currency: USD

4.9  -0.09 (-1.8%)

After market: 4.93 +0.03 (+0.61%)

Fundamental Rating

2

Overall ATYR gets a fundamental rating of 2 out of 10. We evaluated ATYR against 551 industry peers in the Biotechnology industry. The financial health of ATYR is average, but there are quite some concerns on its profitability. ATYR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ATYR has reported negative net income.
ATYR had a negative operating cash flow in the past year.
In the past 5 years ATYR always reported negative net income.
In the past 5 years ATYR always reported negative operating cash flow.
ATYR Yearly Net Income VS EBIT VS OCF VS FCFATYR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of ATYR (-65.21%) is worse than 61.64% of its industry peers.
The Return On Equity of ATYR (-84.49%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.21%
ROE -84.49%
ROIC N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ATYR Yearly ROA, ROE, ROICATYR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATYR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATYR Yearly Profit, Operating, Gross MarginsATYR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

5

2. Health

2.1 Basic Checks

ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATYR has more shares outstanding
Compared to 5 years ago, ATYR has more shares outstanding
The debt/assets ratio for ATYR has been reduced compared to a year ago.
ATYR Yearly Shares OutstandingATYR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATYR Yearly Total Debt VS Total AssetsATYR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ATYR has an Altman-Z score of 2.54. This is not the best score and indicates that ATYR is in the grey zone with still only limited risk for bankruptcy at the moment.
ATYR has a better Altman-Z score (2.54) than 71.64% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ATYR is not too dependend on debt financing.
The Debt to Equity ratio of ATYR (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.54
ROIC/WACCN/A
WACC9.86%
ATYR Yearly LT Debt VS Equity VS FCFATYR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

ATYR has a Current Ratio of 7.79. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
ATYR has a better Current ratio (7.79) than 69.82% of its industry peers.
ATYR has a Quick Ratio of 7.79. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.79, ATYR is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.79
Quick Ratio 7.79
ATYR Yearly Current Assets VS Current LiabilitesATYR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

4

3. Growth

3.1 Past

ATYR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.09%, which is quite good.
Looking at the last year, ATYR shows a very negative growth in Revenue. The Revenue has decreased by -33.43% in the last year.
The Revenue for ATYR have been decreasing by -11.05% on average. This is quite bad
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
Revenue 1Y (TTM)-33.43%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ATYR will show a very strong growth in Earnings Per Share. The EPS will grow by 40.33% on average per year.
ATYR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 383.78% yearly.
EPS Next Y22.03%
EPS Next 2Y8.93%
EPS Next 3Y31.8%
EPS Next 5Y40.33%
Revenue Next Year710.81%
Revenue Next 2Y1165.31%
Revenue Next 3Y854.2%
Revenue Next 5Y383.78%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATYR Yearly Revenue VS EstimatesATYR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ATYR Yearly EPS VS EstimatesATYR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

1

4. Valuation

4.1 Price/Earnings Ratio

ATYR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATYR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATYR Price Earnings VS Forward Price EarningsATYR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATYR Per share dataATYR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ATYR's earnings are expected to grow with 31.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.93%
EPS Next 3Y31.8%

0

5. Dividend

5.1 Amount

ATYR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ATYR PHARMA INC

NASDAQ:ATYR (8/15/2025, 8:06:08 PM)

After market: 4.93 +0.03 (+0.61%)

4.9

-0.09 (-1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners71.26%
Inst Owner ChangeN/A
Ins Owners2.21%
Ins Owner Change1.68%
Market Cap436.10M
Analysts83.53
Price Target19.74 (302.86%)
Short Float %23.42%
Short Ratio5.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.1%
Min EPS beat(2)12.28%
Max EPS beat(2)21.92%
EPS beat(4)3
Avg EPS beat(4)9.24%
Min EPS beat(4)-2.5%
Max EPS beat(4)21.92%
EPS beat(8)6
Avg EPS beat(8)9.28%
EPS beat(12)9
Avg EPS beat(12)11.6%
EPS beat(16)10
Avg EPS beat(16)6.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.87%
PT rev (3m)3.55%
EPS NQ rev (1m)0.3%
EPS NQ rev (3m)1.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-52.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.81
P/tB 5.81
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.21%
ROE -84.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.79
Quick Ratio 7.79
Altman-Z 2.54
F-Score3
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)474.51%
Cap/Depr(5y)299.89%
Cap/Sales(3y)412.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
EPS Next Y22.03%
EPS Next 2Y8.93%
EPS Next 3Y31.8%
EPS Next 5Y40.33%
Revenue 1Y (TTM)-33.43%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A
Revenue Next Year710.81%
Revenue Next 2Y1165.31%
Revenue Next 3Y854.2%
Revenue Next 5Y383.78%
EBIT growth 1Y-14.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.5%
EBIT Next 3Y29.4%
EBIT Next 5Y32.65%
FCF growth 1Y-76.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.1%
OCF growth 3YN/A
OCF growth 5YN/A